Literature DB >> 4067309

Anti-glomerular basement membrane antibody-induced experimental glomerulonephritis: evidence for dose-dependent, direct antibody and complement-induced, cell-independent injury.

N W Boyce, S R Holdsworth.   

Abstract

The immunopathogenesis of anti-glomerular basement membrane antibody-induced glomerulonephritis (anti-GBM-GN) involves the triad of antibody fixation to the glomerular basement membrane, local complement activation and polymorphonuclear leucocyte (PMN) infiltration. We sought to investigate the potential for contributions to renal injury from each component of this triad (i.e., antibody, complement, and PMN). This study compares the ability of antibody to induce injury in normal, PMN-depleted and dual (i.e., PMN + complement)-depleted rabbits by assessing the quantity of kidney-fixed antibody (KFA) necessary to induce proteinuria. (The KFA levels are expressed in micrograms of antibody bound per gram renal cortex.) Normal animals developed significant proteinuria at KFA 60 +/- 6 micrograms/g. PMN-depleted animals were injury free at KFA 60 +/- 6 micrograms/g, but developed heavy proteinuria at KFA 140 +/- 5 micrograms/g. The protection from injury by PMN depletion at lower KFA levels confirms the important contribution of PMN to injury in this model. Furthermore, the demonstration of a clearcut threshold for injury despite PMN-depletion indicates that glomerular antibody deposition and complement activation can cause direct PMN-independent injury. Dual depletion studies showed a significantly higher KFA threshold for injury in PMN + complement-depleted animals than in PMN-depleted, complement intact animals (195 +/- 10 micrograms/g, cf. 140 +/- 5 micrograms/g; p less than 0.01). The occurrence of injury despite dual mediator depletion demonstrates that antibody itself can produce direct, complement and PMN independent renal injury. Together the PMN depletion and dual depletion studies indicate that antibody-induced glomerular complement activation produces direct, PMN-independent renal injury that can be prevented by complement depletion. Thus each of the potential mediators studied is individually capable of producing renal injury in anti-GBM-GN. In addition to the well established injurious role of PMN, this study demonstrates that glomerular complement activation and anti-GBM antibody deposition may both produce neutrophil-independent components of renal injury. The relative contributions of the individual mediators to injury is dependent on the quantity of antibody deposited within the glomerulus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4067309

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Relative contributions of chemo-attractant and terminal components of complement to anti-glomerular basement membrane (GBM) glomerulonephritis.

Authors:  P G Tipping; N W Boyce; S R Holdsworth
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

2.  Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis.

Authors:  Yasuhiko Kanaguchi; Yusuke Suzuki; Ken Osaki; Takeshi Sugaya; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  Nephrol Dial Transplant       Date:  2011-04-27       Impact factor: 5.992

3.  Urine proteome analysis in murine nephrotoxic serum nephritis.

Authors:  Scott E Wenderfer; William P Dubinsky; Mayra Hernandez-Sanabria; Michael C Braun
Journal:  Am J Nephrol       Date:  2009-09-24       Impact factor: 3.754

4.  Cross-reactive myelin antibody induces renal pathology.

Authors:  Lisa K Peterson; Takahisa Masaki; Steven R Wheelwright; Ikuo Tsunoda; Robert S Fujinami
Journal:  Autoimmunity       Date:  2008-11       Impact factor: 2.815

5.  Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury.

Authors:  R J Quigg; C He; A Lim; D Berthiaume; J J Alexander; D Kraus; V M Holers
Journal:  J Exp Med       Date:  1998-10-05       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.